Results 111 to 120 of about 31,381 (233)

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source

tRNA‐Derived Small RNAs in Digestive Cancers: From Translational Regulation to Immune and Extracellular Communication

Cancer Science, EarlyView.
tRNA‐derived small RNAs (tsRNAs) function in digestive cancers across three scales: intracellular translational and metabolic control, extracellular vesicle–mediated immune remodeling, and systemic and host–microbe communication. This review organizes these mechanisms by evidence strength, from well‐established intracellular roles to emerging ...
Wang Xitan, Li Han
wiley   +1 more source

Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance

Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance
内容の要約
openaire  

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

Cancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source

Persistent in vitro nociceptor hyperexcitability and axonal retraction produced by repeated paclitaxel doses

The FEBS Journal, EarlyView.
Repeated paclitaxel exposure causes long‐lasting nociceptor hyperexcitability and axonal retraction in adult sensory neurons. Using a long‐term primary nociceptor culture, we show that hyperexcitability is mediated by sequential upregulation of NaV1.8, TRPV1, TRPA1, and TRPM8 channels.
Angela Lamberti, Victor Moreno Lozano, Asia Fernández‐Carvajal, Antonio Ferrer‐Montiel   +3 more
wiley   +1 more source

Direct tumour–adipocyte contact / Stroma AReactive Invasion Front Area (TAC/SARIFA) predicts adverse outcome in colorectal cancer: a focused evidence synthesis and meta‐analysis

Histopathology, EarlyView.
TAC/SARIFA, defined by direct tumour–adipocyte contact at the invasion front, represents a reproducible, biologically meaningful H&E biomarker with consistent adverse prognostic associations in CRC. Aims Direct tumour‐adipocyte interaction at the invasion front, termed Stroma AReactive Invasion Front Areas (SARIFA), has recently emerged as a novel H&E ...
Nic G Reitsam, Bruno Märkl, Iris D Nagtegaal, Magali Svrcek   +3 more
wiley   +1 more source

Host–Microbe Mechanisms of Fusobacterium nucleatum in Colorectal Cancer

Molecular Oral Microbiology, EarlyView.
Fusobacterium nucleatum and colorectal cancer. ABSTRACT The oral‐derived pathobiont Fusobacterium nucleatum has increasingly been implicated in colorectal cancer (CRC) progression through its ability to modulate inflammatory, immunological, and molecular pathways. F.
Hadda Lyzandra Austríaco Leite, Fernanda Ferreira Lopes   +1 more
wiley   +1 more source

A Novel Modulator of Resistance for Oxaliplatin-Based Therapy for Colorectal Cancer: The ESCRT Family Member VPS4A

Cells
Drug resistance is still one of the main challenges for the treatment of colorectal cancer (CRC). Whilst some resistance mechanisms are well known, from the static therapy success rate, clearly, still much is undiscovered.
Noha M. Abdelrazik, Anjana Patel, Andrew Conn, Christopher W. Sutton, Sriharsha Kantamneni, Steven D. Shnyder   +5 more
doaj   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

Cinnamaldehyde From Cinnamon as a Food‐Derived Bioactive: Phytochemistry, Anticancer Mechanisms, Bioavailability, Nanoformulation and Safety

Food Frontiers, Volume 7, Issue 5, September 2026.
Cinnamaldehyde derived from Cinnamomum species exerts multitarget anticancer effects by promoting oxidative stress, mitochondrial dysfunction, apoptosis, cell‐cycle arrest, autophagy, and epigenetic changes, and by suppressing mitogen‐activated protein kinase (MAPK), phosphoinositide 3‐kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt ...
Gervason Moriasi, Sally Kamau, Gulnaz Seitimova, Shynar Zhumagaliyeva, Javad Sharifi‐Rad, William N. Setzer, Daniela Calina   +6 more
wiley   +1 more source